The first optogenetic "Chimeric Rhodopsin" gene therapy tested in humans. RV-001 starting dose was generally well tolerated in this open-label trial. RV-001 a gene-agnostic approach for RP patients.

retinal sections were incubated with mixed primary antibodies (1:100 anti-PKCα antibody and 1:10000 anti-synaptophysin antibody, or 1:100 anti-PKCα antibody and 1:200 anti-rhodopsin antibody ...

Very little is known about the molecular structures of retinal antigens. One possibility is that an immune response may result from a defect in maintaining tolerance for self-antigens, e. g., ...

Two new compounds may be able to treat retinitis pigmentosa, a group of inherited eye diseases that cause blindness. The compounds were identified using a virtual screening approach.

At the heart of this issue is the protein rhodopsin, which, due to genetic mutations, often misfolds. This misfolding disrupts its function, leading to retinal cell degeneration. Scientists have ...

Treatment with bioavailable small-molecule pharmacochaperones targeting the visual receptor rhodopsin offers a promising approach to prevent retinal photoreceptor degeneration caused by inherited ...

The review concludes with Section VIII, with remarks about the future directions of research on retinal guanylate cyclases. The ventral nerve photoreceptor of the horseshoe crab Limulus polyphemus has ...

In retinitis pigmentosa the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...

In retinitis pigmentosa, the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...

In retinitis pigmentosa, the retina protein rhodopsin is often misfolded due to genetic mutations, causing retinal cells to die off and leading to progressive blindness. Small molecules to correct ...